Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 97 clinical trials
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant (SAFIA)

the combination of Fulvestrant plus Palbociclib as neoadjuvant therapy of hormone-sensitive patients with operable luminal breast cancer. Eligible patients will be assessed upfront using the

white blood cells
serum calcium
calcium
palbociclib
cancer
  • 435 views
  • 27 Feb, 2022
  • 10 locations
Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292). (CAPItello-292)

A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor

  • 32 views
  • 12 May, 2022
  • 15 locations
Palbociclib Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

This study is investigating the combination of palbociclib, letrozole and venetoclax in ER and BCL-2 positive locally advanced or metastatic breast cancer. It is hypothesised that

metastasis
palbociclib
mirena
carcinoma
platelet count
  • 45 views
  • 24 Jan, 2021
  • 3 locations
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and after disease progression under Palbociclib

  • 0 views
  • 27 Jan, 2021
  • 1 location
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

This multicenter, open-label, randomized phase 3 trial will determine if palbociclib and cetuximab (Arm 1) improves overall survival (OS) in comparison to cetuximab monotherapy (Arm 2) in

  • 0 views
  • 27 Apr, 2022
  • 1 location
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)

To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. To evaluate the antitumor activity of …

  • 0 views
  • 19 Apr, 2022
  • 9 locations
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) (HERMIONE-7)

The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.

metastasis
abemaciclib
her2-negative breast cancer
estrogen
progesterone
  • 39 views
  • 25 Mar, 2022
  • 38 locations
Adjuvant Palbociclib in Elderly Patients With Breast Cancer (Appalaches)

Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by

core needle biopsy
metastasis
anthracyclines
hormone therapy
taxane
  • 4 views
  • 11 Apr, 2022
  • 76 locations
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

. Palbociclib (Ibrance) is the name of the investigational agent, which is assessed together with standard anti-hormone therapy in this study. Palbociclib is used to treat patients with hormone receptor

exemestane
hormone therapy
tamoxifen
gnrh
fulvestrant
  • 2 views
  • 19 Feb, 2022
  • 55 locations
High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

This is a phase II, multi-center, single-arm, open-label trial to evaluate efficacy of palbociclib with endocrine therapy as adjuvant treatment in women with C-high/G-high risk ER-positive/HER2

erbb2
her2/neu-negative breast cancer
palbociclib
mammogram
hormone therapy
  • 44 views
  • 05 Mar, 2022
  • 1 location